Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD)

NCT00640809 Phase 4 COMPLETED

To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole

Details

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase	Phase 4
Status	COMPLETED
Enrolment	408
Start date	2003-10
Completion	2004-04

Conditions

• Bowel Diseases, Inflammatory

Interventions

• Celecoxib
• Placebo
• Ibuprofen plus Omeprazole

Primary outcomes

• Number of mucosal breaks in the small bowel for each subject — Day 30

Countries

United States